Medication company Viatris (NASDAQ: VTRS) will be reporting results tomorrow morning. Here’s what you need to know.
Viatris missed analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $3.53 billion, down 8.1% year on year. It was a disappointing quarter for the company, with full-year revenue guidance missing analysts’ expectations.
Is Viatris a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Viatris’s revenue to decline 10.5% year on year to $3.28 billion, a further deceleration from the 1.8% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.49 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Viatris has missed Wall Street’s revenue estimates five times over the last two years.
Looking at Viatris’s peers in the pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 5.5%, missing analysts’ expectations by 3.4%, and Bristol-Myers Squibb reported a revenue decline of 5.6%, topping estimates by 3.9%. Amneal traded down 2.4% following the results while Bristol-Myers Squibb was also down 1.3%.
Read our full analysis of Amneal’s results here and Bristol-Myers Squibb’s results here.
There has been positive sentiment among investors in the pharmaceuticals segment, with share prices up 5.9% on average over the last month. Viatris is up 15.2% during the same time and is heading into earnings with an average analyst price target of $11.75 (compared to the current share price of $8.48).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
